Glocal Career Seminar Z Mike Chirenje MD FRCOG UCSF Bixby Center for Global Health, 550 16 th Street, San Francisco, CA 94158 mchirenje@uzchs-ctrc.org
My Career Background Undergraduate College of Wooster, Ohio USA: Chemistry Major Medical School A M Dogliotti College of Health Science, Monrovia Residency Harare Hospital and Stepping Hill Hospital, Manchester UK through Royal College of Obstetrics & Gynecology (London) Fellowship : Gynecological Oncology, University of Sheffield, UK
My Research Career Pathway During my residency training (in my 30’s) I was stunned by number of Zimbabwean women <50yrs of age, presenting with advanced, incurable cervical cancer. I also observed much lower rates in UK women where screening and treatment for pre-cancer was widely available for eligible women. Upon my return to Zimbabwe in 1993, I established the first Zimbabwean comprehensive cervical cancer screening clinic with colposcopy and treatment facility for pre-cancerous lesions with funding from WHO Research Fellowship Re-entry Grant.
My Research Career Pathway Through USAID grant and collaboration with colleagues from John Hopkins Univ, I was PI for the first study that evaluated performance of a low cost test (visual inspection with acetic acid) to screen women for cervical cancer in low resource settings as alternative to cytology (Pap smear) that is generally not available in low resource settings This Landmark study, published in LANCET 1999, was the pathway for establishing many collaborators in past 25 yrs I also published my observed associations between HIV and HPV and poor treatment outcomes results that have influenced current WHO guidelines for control of cervical cancer among HIV infected women
Landmark Research Attracted Many External Collaborators In 1994 I was co-founder/Director that established collaboration between UZ and UCSF with staff establishment of 2 research nurses to a growth of current 300 in Harare and 7 support staff at UCSF where I have a full time academic appointment in the Dept of O&G. In 1999 I was invited to join NIH sponsored researchers evaluating Female biomedical strategies for prevention of HIV acquisition through heterosexual intercourse: the birth of topical microbicide, oral and systemic PrEP. I was protocol writing team member for HPTN (076,084), HVTN (120) and protocol review team member for several MTN protocols
Landmark Research Attracted Many External Collaborators I was protocol co- Chair for the first PrEP study for HIV prevention in women (VOICE, MTN 003), and current protocol chair for HIV vaccine trial (HVTN 120). I have played pivotal role of membership in Data Safety Monitoring Team for topical microbicides, oral and topical PrEP and HIV vaccine trials. In the past 25 years, I have mentored several middle level investigators to scientific leadership. Some of my mentored scholars who are now independent researchers hold academic posts at Univ of Zim Coll of Health Science, some have risen to Network protocol Chairs, protocol PIs and Chairs at regional and International Conferences
Contribution in Scientific Committees I am a member of the WHO(Geneva) HPV Expert Group, Cervical Cancer Elimination Committee and Scientific Technical Advisory Group I was selected to be co-Chair of HIVR4P 2018 Conference in Madrid, Spain, the only conference that brings together HIV vaccine, topical microbicides and HIV prevention biomedical researches I am a member of International AIDS Vaccine Initiative Scientific Advisory Group. I was Chair of GARDSIL ACCCESS Program that oversaw the delivery of the first 3 million doses of HPV vaccines to 9-13 yr. old girls in 21 low resourced countries from 2007-2014
RECENT RESEARCH AWARDS (2016-2018) Funder Period Total Funding National Institute of Allergy UZ-UCSF Clinical Trials Unit and Infectious Diseases (UM1AI069436) Dec-16 to Nov-20 (NIAID) US$18,596,510 HPTN – 084 (UM1 AI068619) Dec-17 to Nov-22 US$21,340,000 FHI 360; NIAID R13:UZ-UCSF CTU Annual Scientific meeting Jul-17 to Jul-18 (1R13AI132016) NIAID US$56,400 Palliative Cancer Care - Mobile Intervention in Uganda and Nov-18 to Nov-19 Zimbabwe The Medical Research Council (MR/S014535/1) (UK) £47,482 European Developing On demand PrEP (CHAPS) Countries Clinical Trials Apr-18 to Mar-21 (RIA2016MC-1616) EUR 82,878 Partnership (EDCTP) NIAID UCSF Global Health Jul-17 to Jun-18 (2D43TW009343) Fogarty International Centre US$45,120 International Training and Education for Health US$12,000,000 Oct-12 to Sept-18 (I-TECH) (UWSC7379 ) Center for Disease Control per annum
Recommend
More recommend
